Top 5 Companies in Wearable Injectors Domain

Published: June 2026

Wearable injectors are advanced drug delivery devices designed to administer large-volume and high-viscosity therapeutics subcutaneously over an extended period, offering patients a convenient and minimally invasive alternative to traditional intravenous infusions. These devices are increasingly being adopted for the delivery of biologics, including monoclonal antibodies and therapies used in oncology, autoimmune disorders, and chronic diseases, due to their ability to improve patient comfort, and home-based care. Recent technological advancements in wearable injectors have significantly enhanced their functionality, usability, and compatibility with complex biologic formulations. Industry stakeholders are increasingly integrating smart and connected features, such as Bluetooth-enabled monitoring, mobile application connectivity, dose tracking, and real-time adherence monitoring, to support personalized and remote patient monitoring.

The wearable injectors market is anticipated to witness substantial growth in the coming years, driven by the rising prevalence of chronic diseases, expanding biologics pipeline, growing preference for self-administration and decentralized healthcare. Furthermore, increasing investments by pharmaceutical companies in patient-centric delivery platforms and the shift toward reducing hospital visits are expected to further accelerate market expansion during the forecast period.

Roots Analysis has conducted an exhaustive study on Wearable Injectors Market featuring the current market landscape and future opportunity for the companies engaged in healthcare, over a span of next 10 years.

Top 5 Players in the Wearable Injectors Market

1. Becton Dickinson (BD)
2. Enable Injections
3. Insulet
4. West Pharmaceutical Services
5. Ypsomed

The figure below highlights the top 5 players offering wearable injectors:

Discover the Latest Key Market Trends in BCL-2 Inhibitors Market

Interested in exploring 60+ players involved in Wearable Injectors Domain, along with their recent initiatives?

Access Detailed Insights

Discover Below the Details on Leading Wearable Injectors Players in Wearable Injectors Industry

Let us dive deep into the details of the top players in wearable injector domain. These companies were chosen based on Roots Analysis’ proprietary criteria, taking into consideration their device portfolio and recent initiatives. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. Becton Dickinson (BD)

Company Overview

Becton, Dickinson and Company, commonly known as BD, is a leading global medical technology company specializing in the development, manufacturing, and commercialization of medical devices, diagnostic products, and laboratory equipment. Headquartered in Franklin Lakes, the company operates across multiple healthcare segments, and focuses on advancing healthcare delivery through innovation, patient safety, and operational efficiency. It is worth mentioning that the company provides its devices and services to various end-users, including hospitals, laboratories, pharmaceutical companies, and healthcare providers worldwide.

In the wearable injectors domain, BD has been actively involved in developing advanced drug delivery technologies designed to support the administration of biologics and high-volume therapeutics. The company’s wearable injection solutions focus on enabling subcutaneous self-administration, improving patient convenience, reducing hospital dependency, and supporting the shift toward home-based healthcare.

Wearable Injectors Portfolio

The section provides information on the various platforms being offered by Becton Dickinson (BD), along with details on device name, type of device, compatibility with high-viscosity drugs, availability of Bluetooth connectivity, and therapeutic area.

Device Name: BD Libertas™ Wearable Injector
Type of Device: Patch Pump
Compatibility with High-Viscosity Drugs: Yes
Availability of Bluetooth Connectivity: Yes
Therapeutic Area: Other Disorders

Recent Developments

In January 2026, Becton Dickinson and ten23 partnered to support the commercial manufacturing of the BD Libertas wearable injector. The collaboration aims to provide biopharmaceutical companies with an integrated solution for large-volume subcutaneous drug delivery, enabling accelerated product development, and reduced commercialization risks.

In the same month, Becton Dickinson presented its drug delivery innovations at Pharmapack 2026, showcasing technologies designed to support the evolving needs of biologics and patient-centric healthcare.

To know more about the recent initiatives of Becton Dickinson and other players in Wearable Injectors domain, access full report.

2. Enable Injections

Company Overview

Enable Injections is a healthcare technology company focused on developing innovative on-body drug delivery solutions for biologic therapies and high-volume medications. The company specializes in designing patient-centric delivery systems that enable convenient and efficient subcutaneous administration outside traditional clinical settings. Enable Injections collaborates with pharmaceutical and biotechnology companies to support the development and commercialization of advanced drug-device combination products, with a strong emphasis on improving patient comfort, treatment adherence, and overall healthcare accessibility.

Wearable Injectors Portfolio

The section provides information on the various platforms being offered by Enable Injections, along with details on device name, type of device, compatibility with high-viscosity drugs, availability of Bluetooth connectivity, and therapeutic area.

Device Name: enFuse™
Type of Device: Patch Pump
Compatibility with High-Viscosity Drugs: Yes
Availability of Bluetooth Connectivity: Yes

Recent Developments

In May 2026, Enable Injections announced the CE certification of its enFuse on-body injector and syringe transfer system for use in combination with Aspaveli (pegcetacoplan). This development marks a significant step toward expanding patient access to on-body drug delivery solutions for subcutaneous delivery.

In April 2026, Enable Injections and Aptar Digital Health announced a strategic partnership under which Aptar Digital Health will serve as the preferred digital health partner for the enFuse On-Body Delivery System

To know more about the recent initiatives of Enable Injections and other players in Wearable Injectors domain, access full report.

Request Sample Pages

3. Insulet

Company Overview

Insulet is a global medical device company focused on developing innovative technologies for the management of chronic diseases, particularly diabetes. Headquartered in the US, the company is best known for its Omnipod® platform, a tubeless automated insulin delivery system designed to simplify diabetes management. Insulet emphasizes patient-centric innovation, digital connectivity, and ease of use, enabling individuals to manage therapy more conveniently through wearable and automated drug delivery systems. The company continues to expand its presence globally through advancements in connected healthcare technologies and personalized treatment approaches.

Wearable Injectors Portfolio

The section provides information on the various platforms being offered by Insulet, along with details on device name, type of device, compatibility with high-viscosity drugs, availability of Bluetooth connectivity, and therapeutic area.

Device Name: Omnipod DASH Insulin Management System, and Omnipod 5
Type of Device: Patch Pump
Compatibility with High-Viscosity Drugs: Yes
Availability of Bluetooth Connectivity: Yes
Therapeutic Area: Metabolic Disorders (Diabetes)

Recent Developments

In May 2026, Insulet announced a voluntary medical device correction for specific lots of its Omnipod insulin delivery systems, due to a manufacturing issue that could lead to insulin under-delivery.

In March 2026, the company announced new clinical evidence supporting the development of its first fully closed-loop automated insulin delivery (AID) system for the management of type 2 diabetes.

In February 2026, the company announced the expansion of its Omnipod 5 Automated Insulin Delivery (AID) System across key Middle Eastern markets, including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates.

To know more about the recent initiatives of Insulet and other players in Wearable Injectors domain, access full report.

4. West Pharmaceutical Services

Company Overview

West Pharmaceutical Services is a global provider of innovative solutions for injectable drug administration and pharmaceutical packaging systems. Headquartered in Pennsylvania, the company specializes in the development and manufacturing of containment and delivery components for injectable medicines, including stoppers, seals, syringe systems, self-injection devices, and integrated drug delivery technologies. Notably, the firm serves pharmaceutical, biotechnology, and generic drug manufacturers worldwide, with a strong focus on enhancing drug safety, product quality, and patient experience. In the wearable injectors’ domain, the company is actively involved in developing patient-centric, large-volume subcutaneous drug delivery solutions designed for biologics and high-viscosity therapeutics. Additionally, it also collaborates with pharmaceutical partners to provide integrated device and packaging solutions that enhance the performance, reliability, and usability of wearable drug delivery systems.

Wearable Injectors Portfolio

The section provides information on the various platforms being offered by West Pharmaceutical Services, along with details on device name, type of device, compatibility with high-viscosity drugs, availability of Bluetooth connectivity, and therapeutic area.

Device Name: ULTOMRIS (ravulizumab-cwvz) smartdose Injector
Type of Device: Patch Pump
Compatibility with High-Viscosity Drugs: Yes
Availability of Bluetooth Connectivity: Yes
Therapeutic Area: Other Disorders (Paroxysmal Nocturnal Hemoglobinuria (PNH))

Recent Developments

In January 2026, West Pharmaceutical Services announced that it has entered into a definitive agreement with AbbVie to transfer all manufacturing and supply rights associated with the SmartDose® 3.5mL On-Body Delivery System.

In January 2026, the company announced its participation at Pharmapack 2026 in Paris, where the company showcased its expertise in addressing evolving industry challenges and emerging trends related to pharmaceutical packaging, containment, and drug delivery solutions.

To know more about the recent initiatives of West Pharmaceutical Services and other players in Wearable injectors domain, access full report.

5. Ypsomed

Company Overview

Ypsomed is a Switzerland-based medical technology company specializing in the development and manufacturing of injection and infusion systems for self-medication. The company focuses on delivering patient-centric solutions for chronic disease management, particularly in areas such as diabetes, biologics, and other long-term therapies. In the wearable injectors domain, Ypsomed is actively involved in developing advanced wearable and large-volume injection systems designed for subcutaneous administration of biologics and high-viscosity drugs. The company’s wearable injector technologies are focused on enabling convenient at-home treatment, improving patient comfort, and supporting the growing shift toward self-administration and connected healthcare solutions.

Wearable Injectors Portfolio

The section provides information on the various platforms being offered by Ypsomed, along with details on device name, type of device, compatibility with high-viscosity drugs, availability of Bluetooth connectivity, and therapeutic area.

Device Name: YpsoDose, and mylife YpsoPump
Type of Device: Patch Pump and Infusion Pump
Compatibility with High-Viscosity Drugs: No
Availability of Bluetooth Connectivity: Yes

What About other Players in Wearable Injectors Market around the world?

The above article features the top 5 wearable injectors companies, selected from a pool of ~60 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Review Market Landscape

Sources: